BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease

Abstract

Accumulating evidence suggests that BMI1 confers protective effects against Alzheimer’s disease (AD). However, the mechanism remains elusive. Based on recent pathophysiological evidence, we sought for the first time to identify genetic variants in BMI1 as associated with AD biomarkers, including amyloid-β.

Document Details

• Document Type: Pub Defense Publication
• Publication Date: Oct 05, 2021
• Source ID: 10.1186/s13195-021-00906-4

Entities

People

• Andrew J. Saykin
• Bo-hyun Kim
• David A. Bennett
• For The Alzheimer’s Disease Neuroimaging Initiative*
• Jun Pyo Kim
• Kwangsik Nho
• Paula J. Bice
• Sang Won Seo

Organizations

• Alzheimer's Disease Neuroimaging Initiative
• Korea Health Industry Development Institute
• National Institute of General Medical Sciences
• National Institute on Aging
• United States Department of Defense
• United States National Library of Medicine

Tags

Fields of Study

• Biology

Readers

• Oncology (Cancer Research).
• Traumatic Brain Injury (TBI) and Cognitive Aging in the Guam and Border Populations Affected by Alzheimer's Disease and Tau-Associated Dementias.
• Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.

Technology Areas

• Biotechnology